Aelis Farma reports 2022 half-year financial results and confirms its development objectives
BORDEAUX, France–(BUSINESS WIRE)–Regulatory News: Aelis Farma (Paris: AELIS)(ISIN: FR0014007ZB4 – ticker: AELIS, PEA-PME eligible), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, today announces its…